サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1736672

肝がん治療市場：プロセス別、タイプ別、エンドユーザー別、地域別、2026年～2032年

Liver Cancer Treatment Market by Process (Targeted Therapy, Chemotherapy), Type (Hepatocellular Carcinoma, Cholangio Carcinoma), End-User (Hospitals, Clinics), & Region for 2026-2032

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
肝がん治療市場：プロセス別、タイプ別、エンドユーザー別、地域別、2026年～2032年
出版日: 2025年05月06日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝がん治療市場の評価-2026年～2032年

早期診断に関する意識の高まりとイメージング技術の進歩が肝がん治療市場規模の成長を促進しています。Verified Market Researchのアナリストによると、肝がん治療市場は、2024年に約354万米ドルとなり、2032年までに888万米ドルの評価額に達すると予測されています。

肝がん治療市場の急拡大は、治療オプションの改善と患者の転帰の向上を目的とした研究開発活動への投資の増加が主な要因です。これにより、2026年から2032年にかけてのCAGRは13.45%で成長する見込みです。

肝がん治療市場：定義/概要

肝がん治療とは、肝がんの管理を目的とした一連の医療介入と定義され、手術、化学療法、標的療法、免疫療法などさまざまな治療法が含まれます。患者の転帰と生存率を向上させるためには、早期発見とオーダーメイドの治療計画の重要性が強調されています。治療法は、がんの病期、患者の全身状態、特定の腫瘍の特徴に基づいて利用され、治療への個別化アプローチが保証されます。

新規治療薬の開発への注目の高まりと技術の進歩は、肝がん治療市場の主な成長要因として認識されています。また、肝炎感染やアルコール摂取などの要因による肝がんの有病率の上昇も、市場拡大に寄与する重要な要素として認識されています。肝がんとその治療法に関する認識が高まり続ける中、研究開発への投資が優先され、市場の拡大をさらに後押ししています。

研究開発投資の増加が肝がん治療市場に与える影響は？

肝がん治療市場における研究開発投資の増加から、大きなインパクトが観測されています。これらの投資は、治療効果と患者の転帰を高めると期待される新規治療薬の発見と臨床試験に向けられています。その結果、標的療法や免疫療法におけるブレークスルーが達成され、市場全体の成長に寄与しています。

米国国立がん研究所（NCI）によると、米国のがん関連支出総額は2015年の1,830億米ドルから2030年には2,460億米ドルに増加すると予測されており、そのかなりの部分が研究開発努力に充てられています。

さらに、製薬企業と研究機関との協力関係が構築され、開発プロセスが加速しており、その結果、患者の治療選択肢が広がると予想されています。このような技術革新への注力は、肝がん患者のアンメットメディカルニーズへの対応に不可欠であると認識されており、市場拡大の原動力となっています。

規制上の課題の増加は肝がん治療市場の成長にどのような影響を与えているか？

規制上の課題の増加は、肝がん治療市場の成長に大きな影響を与えています。規制当局が課す厳しい承認プロセスが遵守されているため、新しい治療法の市場導入が遅れる可能性があります。こうした課題は、大規模な臨床試験や安全基準の遵守の必要性によってさらに深刻化し、多大な時間と財源を必要とします。

その結果、企業はこれらの障害を効果的に回避するために、薬事戦略や市場参入計画への投資を増やすよう促されています。このような規制上のハードルは、イノベーションを阻害し、生命を救う可能性のある治療の商業化を遅らせる可能性があるため、全体的な影響は業界全体に及んでいます。

目次

第1章 世界の肝がん治療市場のイントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 肝がん治療の世界市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 肝がん治療の世界市場：プロセス別

  • 概要
  • 標的療法
  • 化学療法

第6章 肝がん治療の世界市場：タイプ別

  • 概要
  • 肝細胞がん
  • 胆管がん

第7章 肝がん治療の世界市場：エンドユーザー別

  • 概要
  • 病院
  • 診療所

第8章 肝がん治療の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第9章 世界の肝がん治療市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な発展戦略

第10章 企業プロファイル

  • Merck & Co. Inc.
  • Onyx Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bayer AG
  • Jennerex Biotherapeutics Inc.
  • Celsion Corp
  • Celsion Corp
  • ArQule Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG

第11章 主な発展

  • 製品上市/開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 付録

  • 関連調査
目次
Product Code: 38676

Liver Cancer Treatment Market Valuation - 2026-2032

Increasing awareness regarding early diagnosis and advancements in imaging technologies have been driving the growth of the liver cancer treatment market size. According to the analyst from Verified Market Research, the Liver Cancer Treatment Market is estimated to reach a valuation of USD 8.88 Million By 2032 over the forecast subjugating around USD 3.54 Million valued in 2024.

The rapid expansion of the liver cancer treatment market is primarily driven by increasing investments in research and development activities aimed at improving therapeutic options and enhancing patient outcomes. It enables the market to grow at a CAGR of 13.45% from 2026 to 2032.

Liver Cancer Treatment Market: Definition/ Overview

Liver cancer treatment is defined as a range of medical interventions aimed at managing liver cancer, which includes various therapies such as surgery, chemotherapy, targeted therapy, and immunotherapy. The significance of early detection and tailored treatment plans has been emphasized in improving patient outcomes and survival rates. Treatments are utilized based on the stage of cancer, the overall health of the patient, and specific tumor characteristics, ensuring a personalized approach to care.

Increasing focus on the development of novel therapeutic agents and advancements in technology are being recognized as key growth factors in the liver cancer treatment market. The rising prevalence of liver cancer, driven by factors such as hepatitis infections and alcohol consumption, has also been acknowledged as a crucial element contributing to market expansion. As awareness regarding liver cancer and its treatment options continues to grow, investments in research and development are being prioritized, further supporting market progression.

What Impact is Being Observed from the Rising Investments in Research and Development on the Liver Cancer Treatment Market?

A significant impact is being observed from the rising investments in research and development on the liver cancer treatment market. These investments are being directed toward the discovery and clinical testing of novel therapeutic agents, which are expected to enhance treatment efficacy and patient outcomes. As a result, breakthroughs in targeted therapies and immunotherapies are being achieved, contributing to the overall growth of the market.

According to the National Cancer Institute (NCI), the total national cancer-related expenditure in the United States is projected to increase from USD 183 Billion in 2015 to USD 246 Billion in 2030, a substantial portion of which is dedicated to research and development efforts.

Furthermore, collaborations between pharmaceutical companies and research institutions are being established to accelerate the development process, which is anticipated to result in a wider range of treatment options for patients. This focus on innovation is being recognized as essential in addressing the unmet medical needs of liver cancer patients, thereby driving market expansion.

How are Increasing Regulatory Challenges Affecting the Growth of the Liver Cancer Treatment Market?

Increasing regulatory challenges are affecting the growth of the liver cancer treatment market significantly. Stringent approval processes imposed by regulatory bodies are being observed, which can lead to delays in the introduction of new therapies into the market. These challenges are compounded by the need for extensive clinical trials and compliance with safety standards, which require substantial time and financial resources.

As a result, companies are being encouraged to invest more in regulatory strategies and market access planning to navigate these obstacles effectively. The overall impact of these regulatory hurdles is being felt across the industry, as they can inhibit innovation and slow down the commercialization of potentially life-saving treatments.

Category-Wise Acumens

What Factors are Contributing to the Dominance of Targeted Therapy in the Liver Cancer Treatment Market?

According to VMR analyst, several factors are contributing to the dominance of targeted therapy in the liver cancer treatment market. The specificity of targeted therapies, which focus on particular molecular targets associated with cancer cells, is being recognized for its ability to minimize damage to healthy tissues, leading to fewer side effects compared to traditional treatments. Additionally, significant advancements in molecular diagnostics have enabled the identification of patients who are most likely to benefit from these therapies.

The increasing prevalence of liver cancer, particularly among high-risk populations, is also being acknowledged as a driving force behind the demand for targeted treatment options. Moreover, partnerships between pharmaceutical companies and biotechnology firms are being formed to accelerate the development and commercialization of innovative targeted therapies, further solidifying this segment's leading position in the market.

What are the Key Trends Driving the Rapid Growth of Hepatocellular Carcinoma Treatments?

According to VMR Analyst, key trends driving the rapid growth of hepatocellular carcinoma treatments are being observed as the focus on early detection and improved treatment methodologies continues to increase. The rising incidence of hepatocellular carcinoma, fueled by factors such as chronic hepatitis infections and non-alcoholic fatty liver disease, is being recognized as a critical factor for market expansion. Innovative treatment options, including combination therapies that utilize both targeted agents and immunotherapy, are being developed to enhance treatment efficacy.

Furthermore, growing awareness of liver cancer symptoms and risk factors among healthcare professionals and patients is being emphasized, resulting in earlier diagnoses and timely interventions. The overall impact of these trends is anticipated to lead to a substantial increase in the adoption of hepatocellular carcinoma treatments, contributing significantly to the growth of the liver cancer treatment market.

Country/Region-wise Acumens

What are the Key Factors Contributing to the Dominance of North America in the Liver Cancer Treatment Market?

According to VMR Analyst, the dominance of North America in the liver cancer treatment market is being attributed to several key factors. Advanced healthcare infrastructure and a high level of investment in research and development are being recognized as significant contributors to the region's market leadership. Additionally, the presence of major pharmaceutical companies and biotechnology firms has facilitated the rapid development and commercialization of innovative treatment options. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. biopharmaceutical industry invested an estimated USD 91 Billion in R&D in 2020.

Strong government support for cancer research, along with favorable reimbursement policies for liver cancer treatments, is also being acknowledged as a crucial factor driving market growth. Furthermore, increasing awareness of liver cancer and its treatment options among healthcare providers and patients is being emphasized, leading to higher diagnosis rates and subsequently greater demand for treatment.

How is the Rising Incidence of Liver Cancer in the Asia Pacific Region Impacting the Growth of the Market?

According to VMR Analyst, the rising incidence of liver cancer in the Asia Pacific region is impacting the growth of the liver cancer treatment market significantly. A surge in risk factors, such as chronic hepatitis B and C infections and increasing alcohol consumption, is being observed, contributing to a higher prevalence of the disease in this area. According to the World Health Organization's GLOBOCAN 2020 data, Eastern Asia accounted for about 55.8% of new liver cancer cases globally in 2020. China alone contributed to nearly half of the global liver cancer burden, with an estimated 410,038 new cases in 2020.

The demand for effective treatment options is being fueled by an increasing population and expanding healthcare access in countries such as China and India. Moreover, governmental initiatives aimed at improving cancer care and early detection programs are being implemented, which are expected to enhance treatment rates. As a result, investments in the development of innovative therapies tailored for the unique needs of this region are being prioritized, further driving the market's expansion in Asia Pacific.

Competitive Landscape

The Liver Cancer Treatment Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the liver cancer treatment market include:

Bayer AG

Bristol-Myers Squibb Company

Eisai Co. Ltd.

Elli Lilly and Company

Exelixis, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Liver Cancer Treatment Market Recent Developments

In January 2021, F. Hoffmann-La Roche Ltd. reported updated overall survival statistics from the Phase III Mbrave150 research, which evaluated the enhanced survival rate of liver cancer patients treated with Tecentriq and Avastin.

In November 2020, F. Hoffmann-La Roche Ltd. announced the European Commission's (EU) approval of Tecentriq in conjunction with Avastin for the treatment of liver cancer, intending to expand the product line and increase brand presence in European countries.

In May 2020, the FDA authorized atezolizumab in conjunction with bevacizumab for the initial treatment of liver cancer.

Liver Cancer Treatment Market, By Category

  • Process:
  • Targeted Therapy
  • Chemotherapy
  • Type:
  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • End-User:
  • Hospitals
  • Clinics
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL LIVER CANCER TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL LIVER CANCER TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL LIVER CANCER TREATMENT MARKET, BY PROCESS

  • 5.1 Overview
  • 5.2 Targeted Therapy
  • 5.3 Chemotherapy

6 GLOBAL LIVER CANCER TREATMENT MARKET, BY TYPE

  • 6.1 Overview
  • 6.2 Hepatocellular Carcinoma
  • 6.3 Cholangio Carcinoma

7 GLOBAL LIVER CANCER TREATMENT MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Clinics

8 GLOBAL LIVER CANCER TREATMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL LIVER CANCER TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Merck & Co. Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Onyx Pharmaceuticals Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Alnylam Pharmaceuticals, Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Bayer AG
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Jennerex Biotherapeutics Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Celsion Corp
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Celsion Corp
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 ArQule Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.10 Pfizer Inc.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.10 F. Hoffmann-La Roche AG
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research